China Biologic Products, enjoying higher prices for its products and lower operating expenses, reported a very substantial 54% rise in Q3 revenues to $13.8 million. Net income climbed an even larger 98% to $4.5 million, which works out to 21 cents per share, fully diluted. Prices for China Biologic’s plasma-centered portfolio increased 22% during the period, a major factor in the company’s success. More details...

Stock Symbol: (OTCBB: CBPO)